Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease
We have developed a new model that provides a framework for defining the magnitude of treatment effect on TKV that would support accelerated approval of a drug for autosomal dominant polycystic kidney disease.
Authors
- Lilian Golzarri‐Arroyo (ORCID: https://orcid.org/0000-0002-1221-6701)
- MICHAL MRUG
- Frederic F. Rahbari-Oskoui (ORCID: https://orcid.org/0000-0001-8933-4880)
- Yu Asl
- Rekha Garg
- Vicente Torres
- C. Parker
- Peter Harris
- Edmund C. Lee
- Arlene B. Chapman
- Douglas P. Landsittel
Institutions
- Regulus Therapeutics (United States) (US)
- Mayo Clinic (US)
- Emory University (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- Birmingham VA Medical Center (US)
- Indiana University Bloomington (US)
- University of Kansas Medical Center (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.2215/cjn.0000000992
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00